AHCO
BEARISH
$10.6
Live
AdaptHealth Corp. · NASDAQ
Target $12.88
(+21.5%)
$7.11
52W Range
$11.17
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.44B
P/E
N/A
ROE
-4.3%
Profit margin
-2.2%
Debt/Equity
1.25
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AHCO's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, with negative ROE (-4.25%) and declining revenue (-1.20% YoY). The absence of an Altman Z-Score raises concern about bankruptcy risk, while the Graham Number and intrinsic value are unavailable, suggesting no reliable fundamental valuation anchor. Despite a modest 1Y return of +10.2%, the stock has underperformed over 3Y (-20.2%) and 5Y (-72.3%), reflecting deep structural issues. Analysts recommend 'buy' with a target of $12.88, but this optimism is not supported by deteriorating fundamentals or consistent earnings beats.
Key Strengths
Positive operating margin (6.20%) indicates some operational efficiency despite losses
Price/Sales of 0.44 suggests potential undervaluation relative to revenue
Recent Q/Q EPS growth of +68.8% shows possible short-term recovery momentum
Insider sentiment at 60/100 reflects moderate confidence despite recent selling
1Y price return of +10.2% indicates recent market resilience
Key Risks
Piotroski F-Score of 2/9 signals severe financial weakness and poor profitability trends
Negative profit margin (-2.18%) and declining revenue (-1.20% YoY) indicate deteriorating business fundamentals
Debt/Equity ratio of 1.25 is elevated, especially with a current ratio of 1.02 and quick ratio of 0.71, indicating liquidity strain
Insider selling of $0.05M in the last 6 months signals bearish sentiment from within the company
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -27.98%) undermine credibility and investor confidence
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
55
30
40
25
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (2/9), Negative ROE and profit margin, Declining revenue and earnings, Lack of Altman Z-Score, High insider selling
Confidence
85%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.44 is low, suggesting potential undervaluation
- Price/Book of 0.92 is below 1.0, indicating potential asset coverage
Watchpoints
- No Graham Number or intrinsic value available
- Forward P/E of 8.52 is misleading without reliable earnings
- Negative profit margin undermines valuation assumptions
Future
30/100
Ref Growth rates
Positives
- Recent Q/Q EPS growth of +68.8% suggests possible turnaround
- Analyst target price of $12.88 implies growth expectations
Watchpoints
- Revenue growth is negative (-1.20% YoY)
- Earnings growth is negative (-35.7% YoY)
- No consistent earnings beat history in the last 4 quarters
Past
40/100
Ref Historical trends
Positives
- Historical EPS surprises include strong positive outliers (e.g., +167.2%)
- Some quarters show significant beat performance (e.g., +93.3%)
Watchpoints
- Recent streak of 4 consecutive misses with average surprise of -27.98%
- 5Y price change of -72.3% reflects long-term underperformance
- 2023-02-26 and 2023-05-09 saw massive misses (-84.0% and -51.5%)
Health
25/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Operating margin of 6.20% shows some cost control
Watchpoints
- Piotroski F-Score of 2/9 is extremely low (below 4 = weak)
- Negative ROE (-4.25%) and ROA (2.90%) indicate poor capital efficiency
- Debt/Equity of 1.25 is high for a company with weak profitability
- Current ratio of 1.02 and quick ratio of 0.71 suggest liquidity pressure
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$10.6
Analyst Target
$12.88
Upside/Downside
+21.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AHCO and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AHCO
AdaptHealth Corp.
Primary
|
-72.3% | -20.2% | +10.2% | +14.1% | +0.5% | +11.6% |
|
AVAH
Aveanna Healthcare Holdings Inc.
Peer
|
-42.4% | +506.1% | +26.3% | -14.5% | -9.6% | -1.7% |
|
GLUE
Monte Rosa Therapeutics, Inc.
Peer
|
-14.8% | +121.2% | +344.6% | +113.4% | +4.5% | +5.6% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
|
ARDX
Ardelyx, Inc.
Peer
|
-17.1% | +46.3% | +6.6% | -12.6% | -20.4% | -6.6% |
AHC
AdaptHealth Corp.
Primary
5Y
-72.3%
3Y
-20.2%
1Y
+10.2%
6M
+14.1%
1M
+0.5%
1W
+11.6%
AVA
Aveanna Healthcare Holdings Inc.
Peer
5Y
-42.4%
3Y
+506.1%
1Y
+26.3%
6M
-14.5%
1M
-9.6%
1W
-1.7%
GLU
Monte Rosa Therapeutics, Inc.
Peer
5Y
-14.8%
3Y
+121.2%
1Y
+344.6%
6M
+113.4%
1M
+4.5%
1W
+5.6%
BCR
BioCryst Pharmaceuticals, Inc.
Peer
5Y
-25.9%
3Y
-38.3%
1Y
-12.2%
6M
-20.6%
1M
-11.8%
1W
+1.9%
ARD
Ardelyx, Inc.
Peer
5Y
-17.1%
3Y
+46.3%
1Y
+6.6%
6M
-12.6%
1M
-20.4%
1W
-6.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
8.52
PEG Ratio
N/A
P/B Ratio
0.92
P/S Ratio
0.44
EV/Revenue
1.0
EV/EBITDA
5.53
Market Cap
$1.44B
Profitability
Profit margins and return metrics
Profit Margin
-2.18%
Operating Margin
6.2%
Gross Margin
20.89%
ROE
-4.25%
ROA
2.9%
Growth
Revenue and earnings growth rates
Revenue Growth
-1.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.25
Moderate
Current Ratio
1.02
Good
Quick Ratio
0.71
Poor
Cash/Share
$0.78
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-24
$0.27
-20.8% surprise
2025-11-04
$0.16
-32.3% surprise
2025-08-05
$0.1
-30.9% surprise
Healthcare Sector Comparison
Comparing AHCO against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-4.25%
This Stock
vs
-101.52%
Sector Avg
-95.8%
(Below Avg)
Profit Margin
-2.18%
This Stock
vs
-12.47%
Sector Avg
-82.5%
(Weaker)
Debt to Equity
1.25
This Stock
vs
3.4
Sector Avg
-63.3%
(Less Debt)
Revenue Growth
-1.2%
This Stock
vs
124.21%
Sector Avg
-101.0%
(Slower)
Current Ratio
1.02
This Stock
vs
4.56
Sector Avg
-77.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | - | -4.3% | -2.2% | $10.6 | |
|
AVAH
Aveanna Healthcare Holdings Inc.
|
BEARISH | $1.44B | 18.68 | -% | 3.3% | $6.91 | Compare |
|
GLUE
Monte Rosa Therapeutics, Inc.
|
NEUTRAL | $1.44B | - | -16.9% | -31.2% | $18.05 | Compare |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 | Compare |
|
ARDX
Ardelyx, Inc.
|
NEUTRAL | $1.42B | - | -36.2% | -15.1% | $5.78 | Compare |
AHCO
AdaptHealth Corp.
BEARISH
Mkt Cap
$1.4B
P/E
-
ROE
-4.3%
Price
$10.6
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | WEAVER SUSAN T. | Director | Gift | 73,472 | - |
| 2026-02-27 | WOLF DALE B | Director | Purchase | 8,000 | $71,680 |
| 2026-02-26 | REW RICHARD W. II | General Counsel | Purchase | 5,000 | $44,550 |
| 2026-01-30 | REW RICHARD W. II | General Counsel | Stock Award | 53,688 | - |
| 2026-01-30 | FOSTER SUZANNE | Chief Executive Officer | Stock Award | 329,449 | - |
| 2026-01-30 | CLEMENS JASON A | Chief Financial Officer | Stock Award | 126,899 | - |
| 2026-01-30 | ARCHBOLD CHRISTINE E. | Officer | Stock Award | 32,213 | - |
| 2026-01-30 | PRAST ALBERT A. | Chief Technology Officer | Stock Award | 63,449 | - |
| 2026-01-30 | BARNHART TOBY SCOTT | Chief Operating Officer | Stock Award | 68,330 | - |
| 2026-01-30 | SCHUSTER RUSSELL E. III | Officer | Stock Award | 48,807 | - |
| 2026-01-30 | MCFADDEN DANIEL EDWARD | Officer | Stock Award | 29,284 | - |
| 2026-01-09 | BELINFANTI GREGORY A | Director | Stock Award | 11,776 | - |
| 2026-01-09 | LUNDBERG THEODORE B. | Director | Stock Award | 13,740 | - |
| 2025-12-04 | WILLIAMS DAVID SOLOMON III | Director | Sale | 5,000 | $47,150 |
WEAVER SUSAN T.
Director
2026-03-05
73,472 shares
WOLF DALE B
Director
2026-02-27
8,000 shares
·
$71,680
REW RICHARD W. II
General Counsel
2026-02-26
5,000 shares
·
$44,550
REW RICHARD W. II
General Counsel
2026-01-30
53,688 shares
FOSTER SUZANNE
Chief Executive Officer
2026-01-30
329,449 shares
CLEMENS JASON A
Chief Financial Officer
2026-01-30
126,899 shares
ARCHBOLD CHRISTINE E.
Officer
2026-01-30
32,213 shares
PRAST ALBERT A.
Chief Technology Officer
2026-01-30
63,449 shares
BARNHART TOBY SCOTT
Chief Operating Officer
2026-01-30
68,330 shares
SCHUSTER RUSSELL E. III
Officer
2026-01-30
48,807 shares
MCFADDEN DANIEL EDWARD
Officer
2026-01-30
29,284 shares
BELINFANTI GREGORY A
Director
2026-01-09
11,776 shares
LUNDBERG THEODORE B.
Director
2026-01-09
13,740 shares
WILLIAMS DAVID SOLOMON III
Director
2025-12-04
5,000 shares
·
$47,150
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
8 analysts
Leerink Partners
2026-02-26
Outperform
Outperform
Canaccord Genuity
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning AHCO from our newsroom.
Newest → oldest
No matching news yet.